__timestamp | HUTCHMED (China) Limited | TG Therapeutics, Inc. |
---|---|---|
Wednesday, January 1, 2014 | 26684000 | 24518692 |
Thursday, January 1, 2015 | 29829000 | 19886580 |
Friday, January 1, 2016 | 39578000 | 12631689 |
Sunday, January 1, 2017 | 43277000 | 21977998 |
Monday, January 1, 2018 | 48645000 | 20759000 |
Tuesday, January 1, 2019 | 52934000 | 20838000 |
Wednesday, January 1, 2020 | 61349000 | 121812000 |
Friday, January 1, 2021 | 127125000 | 152137000 |
Saturday, January 1, 2022 | 136106000 | 83231000 |
Sunday, January 1, 2023 | 133175999 | 122706000 |
Unleashing the power of data
In the competitive world of pharmaceuticals, managing Selling, General, and Administrative (SG&A) expenses is crucial for profitability. Over the past decade, TG Therapeutics, Inc. and HUTCHMED (China) Limited have shown distinct strategies in optimizing these costs. From 2014 to 2023, HUTCHMED's SG&A expenses grew by approximately 400%, peaking in 2022. Meanwhile, TG Therapeutics saw a more volatile trend, with a significant spike in 2021, where expenses surged by over 600% compared to 2016. Despite these fluctuations, both companies have demonstrated resilience, with TG Therapeutics showing a notable reduction in 2022. This data highlights the dynamic nature of cost management in the pharmaceutical industry, where strategic financial planning can significantly impact a company's bottom line. As these companies continue to innovate, their ability to control SG&A expenses will remain a key factor in their financial health.
Breaking Down SG&A Expenses: Johnson & Johnson vs TG Therapeutics, Inc.
Operational Costs Compared: SG&A Analysis of TG Therapeutics, Inc. and MorphoSys AG
Who Optimizes SG&A Costs Better? TG Therapeutics, Inc. or Agios Pharmaceuticals, Inc.
Comparing SG&A Expenses: TG Therapeutics, Inc. vs Celldex Therapeutics, Inc. Trends and Insights
CRISPR Therapeutics AG or HUTCHMED (China) Limited: Who Manages SG&A Costs Better?
Cost Management Insights: SG&A Expenses for Veracyte, Inc. and HUTCHMED (China) Limited
Selling, General, and Administrative Costs: MorphoSys AG vs HUTCHMED (China) Limited
Operational Costs Compared: SG&A Analysis of Catalyst Pharmaceuticals, Inc. and HUTCHMED (China) Limited
HUTCHMED (China) Limited vs ImmunityBio, Inc.: SG&A Expense Trends
Comparing SG&A Expenses: HUTCHMED (China) Limited vs Amphastar Pharmaceuticals, Inc. Trends and Insights
HUTCHMED (China) Limited or Travere Therapeutics, Inc.: Who Manages SG&A Costs Better?
Operational Costs Compared: SG&A Analysis of HUTCHMED (China) Limited and Viridian Therapeutics, Inc.